Mitralign attracts CV big guns in series C:
This article was originally published in Clinica
Executive Summary
Mitralign, a Tewksbury, Massachusetts company developing a catheter-based technology for treating mitral valve regurgitation, has added Medtronic and Johnson & Johnson to its list of investors. The two medtech heavyweights led a $24m series C financing round, in which Mitralign also welcomed other new investors, including Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Mitralign will use the funds to complete initial clinical studies and gain CE-marking for its system.